Vascular endothelial growth factor receptor 3 antagonists - Pipeline Insight, 2024

This “Vascular endothelial growth factor receptor 3 antagonists - Pipeline Insight, 2024” report provides comprehensive insights about 18+ companies and 18+ pipeline drugs in Vascular endothelial growth factor receptor 3 antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Vascular endothelial growth factor receptor 3 antagonists Understanding

Vascular endothelial growth factor receptor 3 antagonists: Overview

Vascular endothelial growth factor receptor 3 (VEGFR-3) binds VEGF-C and VEGF-D and is essential for the development of the lymphatic vasculature. Experimental tumors that overexpress VEGFR-3 ligands induce lymphatic vessel sprouting and enlargement and show enhanced metastasis to regional lymph nodes and beyond, whereas a soluble form of VEGFR-3 that blocks receptor signaling inhibits these changes and metastasis. VEGFR-3 is also essential for the early blood vessel development in embryos and is up-regulated in tumor angiogenesis. A number of different strategies to inhibit VEGF signal transduction are in development and they include the development of humanized neutralizing anti-VEGF monoclonal antibodies, receptor antagonists, soluble receptors, antagonistic VEGF mutants, and inhibitors of VEGF receptor function. These agents can be divided in two broad classes, namely agents designed to target the VEGF activity and agents designed to target the surface receptor function.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Vascular endothelial growth factor receptor 3 antagonists R&D. The therapies under development are focused on novel approaches for Vascular endothelial growth factor receptor 3 antagonists.

Vascular endothelial growth factor receptor 3 antagonists Emerging Drugs Chapters

This segment of the Vascular endothelial growth factor receptor 3 antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Vascular endothelial growth factor receptor 3 antagonists Emerging Drugs

Nintedanib: Boehringer Ingelheim Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC). It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one of only two disease-modifying therapies available and indicated for the condition (the other being Pirfenidone) and as such is used as a first-line treatment following diagnosis to slow down the progressive loss of lung function. As a chemotherapeutic agent for NSCLC, nintedanib, in combination with Docetaxel, is reserved for patients who have tried and failed first-line chemotherapeutic options. The drug is being evaluated in phase III stage of clinical trials to treat colorectal and ovariancancer.

Lenvatinib: Eisai Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRa), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression. In particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types ofcancers.

Vascular endothelial growth factor receptor 3 antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Vascular endothelial growth factor receptor 3 antagonists drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Vascular endothelial growth factor receptor 3 antagonists

There are approx. 18+ key companies which are developing the Vascular endothelial growth factor receptor 3 antagonists. The companies which have their Vascular endothelial growth factor receptor 3 antagonists drug candidates in the most advanced stage, i.e. Phase III include, Boehringer Ingelheim.

Phases

This report covers around 18+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Vascular endothelial growth factor receptor 3 antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Vascular endothelial growth factor receptor 3 antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Vascular endothelial growth factor receptor 3 antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vascular endothelial growth factor receptor 3 antagonists drugs.

Vascular endothelial growth factor receptor 3 antagonists Report Insights

• Vascular endothelial growth factor receptor 3 antagonists Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Vascular endothelial growth factor receptor 3 antagonists Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Vascular endothelial growth factor receptor 3 antagonists drugs?
• How many Vascular endothelial growth factor receptor 3 antagonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vascular endothelial growth factor receptor 3 antagonists?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Vascular endothelial growth factor receptor 3 antagonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Vascular endothelial growth factor receptor 3 antagonists and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Boehringer Ingelheim
• Eisai
• HUTCMED
• Advenchen Laboratories
• Mirati Therapeutics
• Pfizer
• Ai VivaBioPharma
• Aerie Pharmaceuticals
• Avalyn Pharmaceuticals
• Xspray Pharma
• Lynkcell
• Bayer
• Metagone Biotech
• Chipscreen Biosciences
• Jiangsu Hengrui Medicine
• Roche
• AstraZeneca
• Loxo oncology
• Clearside Biomedical

Key Products

• Nintedanib
• Lenvatinib
• LOXO 292
• AZD-2171
• CLS 1002
• Surufatinib
• Catequentinib
• Sitravatinib
• Axitinib
• AIV 007
• AR-14034
• AP02
• HyNap-Sora
• Pazopanib intravitreal
• LYN 00101
• BAY-57-9352
• SHR 1020
• MG D 1609
• CS-2164

This product will be delivered within 2-4 business days.